PE Goss

Breast Cancer Incidence in the Randomized PEARL Trial of Lasofoxifene in Postmenopausal Osteoporotic Women

Andrea Z. LaCroix, TJ Powles, C. Kent Osborne et al. · JNCI Journal of the National Cancer Institute · 2010 · 169 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17

Abstract S1-1: Final Analysis of NCIC CTG MA.27: A Randomized Phase III Trial of Exemestane Versus Anastrozole in Postmenopausal Women with Hormone Receptor Positive Primary Breast Cancer

PE Goss, JN Ingle, J-AW Chapman et al. · Cancer Research · 2010 · 24 citations

Medicine, Oncology, Pharmacology +16

NCIC CTG MA.17: Intent to treat analysis (ITT) of randomized patients after a median follow-up of 54 months

J. Ingle, Dongping Tu, L. E. Shepherd et al. · Journal of Clinical Oncology · 2006 · 22 citations

Medicine, Biostatistics, Oncology +13

P3-16-05: A Phase II Trial Expansion Cohort of the PARP Inhibitor Veliparib (ABT888) and Temozolomide in BRCA1/2 Associated Metastatic Breast Cancer.

SJ Isakoff, Beth Overmoyer, NM Tung et al. · Cancer Research · 2011 · 19 citations

Medicine, Oncology, Pharmacology +15

Abstract S1-9: Comparative Performance of Breast Cancer Index (BCI) vs. Oncotype Dx and IHC4 in the Prediction of Late Recurrence in Hormonal Receptor-Positive Lymph Node-Negative Breast Cancer Patients: A TransATAC Study

DC Sgroi, Ivana Šestak, Jack Cuzick et al. · Cancer Research · 2012 · 18 citations

Medicine, Oncology, Breast Oncology +13